Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF SYS6010 IN COMBINATION WITH ENLONSTOBART FOR THE TREATMENT OF DRIVER GENE-NEGATIVE NON-SMALL CELL LUNG CANCER OFFICIALLY INITIATED IN CHINA

VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF SYS6010 IN COMBINATION WITH ENLONSTOBART FOR THE TREATMENT OF DRIVER GENE-NEGATIVE NON-SMALL CELL LUNG CANCER OFFICIALLY INITIATED IN CHINA

June 26, 2026

a260626_00.png

Next: VOLUNTARY ANNOUNCEMENT - OCTREOTIDE LONG-ACTING INJECTION (SYHX2008) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC PHARMACEUTICAL GROUP LIMITED All Rights Reserved | 冀ICP备05003393号

Wechat